Le Lézard
Classified in: Health
Subject: ATY

Parker Waichman LLP Comments: DePuy Synthes Attune Knee Device Lawsuits Mounting



PORT WASHINGTON, N.Y., Oct. 5, 2017 /PRNewswire/ -- Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims injured by allegedly defective drugs and medical devices, is commenting on DePuy Synthes Attune Knee Replacement problems. Reports submitted to the U.S. Food and Drug Administration (FDA) reveal an increased number of Attune failures are due, allegedly, to loosening?or debonding?at the cement border of the tibial baseplate. Premature failure typically takes place one-two years following implant, if not earlier. Such debonding of the tibial baseplate or tray leads to pain, swelling, inflammation, infection, instability, severe bone and/or muscle loss and damage, and other injuries, all necessitating more medical procedures or surgeries to remove and replace the device (revision surgery). Revision surgery is generally more painful, difficult, and costlier than initial surgery, especially if bone loss has developed. Revision surgery also generally involves longer, more complex therapy ad recovery.

"Parker Waichman represents many patients implanted with the Attune knee implant system who have subsequently suffered from serious and painful complications," says Keith Gitman, Managing Attorney. Parker Waichman is a nationwide law firm representing victims of the Attune knee system and continues to offer free legal reviews to individuals who allegedly suffered complications related to the Attune system.

Symptoms of Attune Knee implant failure may include instability and loosening, unusual swelling, persistent pain, warmth or heat in the knee, loss of or failure to bond of the system to bond to the bone, worn components, fracture, loss of osseointegration (loss of direct structural and functional connection between ordered, living bone and the surface of a load-carrying implant), and metal shedding debris.

Also, according to Mr. Gitman, "Whistleblowers are crucial in detecting and stopping fraud and are critical to ending illegal employer activities that may cause harm to patients." Mr. Gitman adds that, "Whistleblowers have long been crucial in helping to stop illegal activities by various entities, including medical device makers. Parker Waichman has also been involved in resolving cases involving fraud and have been equally important in maintaining whistleblower anonymity in these cases."

"This case opens up the potential for other cases of fraud to emerge," said Mr. Gitman.  "When medical device companies take part in illegal or unethical activities such as releasing potentially defective devices to the market, they are defrauding unsuspecting patients and physicians," added Mr. Gitman.

Filing a DePuy Synthes Attune Knee Replacement System Lawsuit

Parker Waichman LLP supports efforts to protect whistleblowers and offers free case evaluations to those individuals who believe their companies may be involved in wrongdoings.  Parker Waichman has also long represented clients in medical device injury lawsuits. If you or someone you know is interested in filing a DePuy Synthes Attune Knee Replacement System lawsuit, or if you believe that a device maker is committing fraudulent activities and would like to maintain your anonymity, contact Parker Waichman LLP at the firm's website at www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

SOURCE Parker Waichman LLP


These press releases may also interest you

at 13:00
Orig3n, a Boston-based biotech company pioneering the future of health through genetics and regenerative medicine, today announced that its co-founders, Robin Y. Smith, CEO, and Kate Blanchard, COO, are finalists for the Ernest and Young Entrepreneur...

at 13:00
The "Infantile Spasms Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The report predicts the global infantile spasms therapeutics market to...

at 13:00
Members of the Union of Canadian Correctional Officers (UCCO-SACC-CSN) will be demonstrating on Monday, June 25, in front of the office of Ginette Petitpas Taylor, Canada's Minister of Health. The correctional officers are asking the government to...

at 13:00
Mezzion Pharma and the National Heart, Lung, and Blood Institute (NHLBI) today announced that it has completed enrollment of their FUEL trial, a pivotal Phase 3 efficacy and safety trial of udenafil for the treatment of adolescents with congenital...

at 12:51
Unable to carry signals based on sights and sounds to the genes that record memories, a broken shuttle protein may hinder learning in patients with intellectual disability, schizophrenia, and autism. This is the...

at 12:47
FSD Pharma Inc. ("FSD" or the "Company") , welcomes the official passing of Bill C-45, the Cannabis Act in Canada. Bill C-45 formally received Royal Assent Thursday morning in Canada's Parliament. The bill officially...




News published on 5 october 2017 at 08:45 and distributed by: